

AstraZeneca is GAINING STEAM IN HEME



40+ years of heritage in oncology is being put to work:

IN **15+**
CLINICAL TRIALS
of new blood cancer investigational agents¹



To potentially reach

350,000+
PATIENTS



IN **80+**
COUNTRIES



To help address the complexities of

130 BLOOD
CANCER SUBTYPES²



AstraZeneca strives to be a scientific leader in hematology for the 4 million people living with blood cancers* worldwide as of 2022.³

**Advancing a diverse
and innovative pipeline
spanning across:**

- ✓ Antibody-drug conjugates
- ✓ Immuno-oncology
- ✓ Cell therapy
- ✓ DNA damage response
- ✓ Epigenetics
- ✓ Tumor drivers and resistance

*Blood cancers including leukemia, lymphoma, and myeloma.

References: **1.** AstraZeneca. Oncology Pipeline—Hematological Trials. Accessed September 3, 2025. <https://www.az-oncology-pipeline.com/tumour-type/568/indications>. **2.** Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. *Leukemia*. 2022;36:1720-1748. **3.** Ferlay J, Ervik M, Lam F, et al. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Accessed September 3, 2025. <https://gco.iarc.who.int/media/globocan/factsheets/populations/900-world-fact-sheet.pdf>.